Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Inhibiting autophagy potentiates the anticancer activity of IFN1@/IFNα in chronic myeloid leukemia cells.

Zhu S, Cao L, Yu Y, Yang L, Yang M, Liu K, Huang J, Kang R, Livesey KM, Tang D.

Autophagy. 2013 Mar;9(3):317-27. doi: 10.4161/auto.22923. Epub 2012 Dec 14.

2.

Inhibition of autophagy augments the anticancer activity of α-mangostin in chronic myeloid leukemia cells.

Chen JJ, Long ZJ, Xu DF, Xiao RZ, Liu LL, Xu ZF, Qiu SX, Lin DJ, Liu Q.

Leuk Lymphoma. 2014 Mar;55(3):628-38. doi: 10.3109/10428194.2013.802312. Epub 2013 Jul 18.

PMID:
23734655
3.

Signaling via the interferon-alpha receptor in chronic myelogenous leukemia cells.

Verma A, Platanias LC.

Leuk Lymphoma. 2002 Apr;43(4):703-9. Review.

PMID:
12153154
4.

Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.

Shinohara H, Taniguchi K, Kumazaki M, Yamada N, Ito Y, Otsuki Y, Uno B, Hayakawa F, Minami Y, Naoe T, Akao Y.

Cancer Lett. 2015 Apr 28;360(1):28-38. doi: 10.1016/j.canlet.2015.01.039. Epub 2015 Jan 30.

PMID:
25644089
5.

Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro.

Tong Y, Liu YY, You LS, Qian WB.

Acta Pharmacol Sin. 2012 Apr;33(4):542-50. doi: 10.1038/aps.2011.192. Epub 2012 Mar 12.

6.

The role of TC-PTP (PTPN2) in modulating sensitivity to imatinib and interferon-α in CML cell line, KT-1 cells.

Nishiyama-Fujita Y, Shimizu T, Sagawa M, Uchida H, Kizaki M.

Leuk Res. 2013 Sep;37(9):1150-5. doi: 10.1016/j.leukres.2013.05.008. Epub 2013 Jun 4.

PMID:
23759247
7.

Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.

Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, Raynaud S, Auberger P.

Cancer Res. 2010 Feb 1;70(3):1042-52. doi: 10.1158/0008-5472.CAN-09-3537. Epub 2010 Jan 26.

8.

Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.

Liu JH, Liu CC, Yen CC, Gau JP, Wang WS, Tzeng CH.

Int J Cancer. 2009 Jul 1;125(1):71-7. doi: 10.1002/ijc.24329.

9.

Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells.

Song P, Ye L, Fan J, Li Y, Zeng X, Wang Z, Wang S, Zhang G, Yang P, Cao Z, Ju D.

Oncotarget. 2015 Feb 28;6(6):3861-73.

10.

Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P.

Cancer Res. 2005 Oct 15;65(20):9436-44.

11.

Reactive oxygen species-mediated activation of JNK and down-regulation of DAXX are critically involved in penta-O-galloyl-beta-d-glucose-induced apoptosis in chronic myeloid leukemia K562 cells.

Kwon TR, Jeong SJ, Lee HJ, Lee HJ, Sohn EJ, Jung JH, Kim JH, Jung DB, Lu J, Kim SH.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):530-7. doi: 10.1016/j.bbrc.2012.06.150. Epub 2012 Jul 6.

PMID:
22771329
12.
13.

Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings.

Zhu Jf, Li Zj, Zhang Gs, Meng K, Kuang Wy, Li J, Zhou Xf, Li Rj, Peng Hl, Dai Cw, Shen JK, Gong Fj, Xu Yx, Liu Sf.

PLoS One. 2011;6(8):e23720. doi: 10.1371/journal.pone.0023720. Epub 2011 Aug 22.

14.

Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.

Liao HF, Su YC, Zheng ZY, Jhih Cai C, Hou MH, Chao KS, Chen YJ.

Biomed Pharmacother. 2012 Jul;66(5):378-83. doi: 10.1016/j.biopha.2011.12.008. Epub 2012 Feb 16.

PMID:
22397755
15.

Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of β-catenin and STAT1 in chronic myeloid leukemia cells.

Yang KT, Wang MC, Chen JY, Hsu MC, Hung WC.

J Cell Physiol. 2011 Nov;226(11):2849-56. doi: 10.1002/jcp.22633.

PMID:
21935931
16.

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.

Blood. 2005 Apr 15;105(8):3303-11. Epub 2004 Dec 30.

17.
18.

Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression.

Landolfo S, Guarini A, Riera L, Gariglio M, Gribaudo G, Cignetti A, Cordone I, Montefusco E, Mandelli F, Foa R.

Hematol J. 2000;1(1):7-14.

PMID:
11920164
19.

CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.

Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN.

Blood. 2000 Sep 15;96(6):2246-53.

20.

Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.

Samudio I, Kurinna S, Ruvolo P, Korchin B, Kantarjian H, Beran M, Dunner K Jr, Kondo S, Andreeff M, Konopleva M.

Mol Cancer Ther. 2008 May;7(5):1130-9. doi: 10.1158/1535-7163.MCT-07-0553.

Supplemental Content

Support Center